![These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009 These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=images-6.jpg&id=579191)
These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009
![The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial - ScienceDirect The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2212137418301131-gr1.jpg)
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial - ScienceDirect
![A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma - European Urology A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma - European Urology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9c0e9f72-ad6c-480e-940d-5d30e25b3885/gr1_lrg.jpg)
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma - European Urology
![Two‐year outcomes in de novo renal transplant recipients receiving everolimus‐facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study - Berger - 2019 - American Journal of Transplantation - Wiley Online Library Two‐year outcomes in de novo renal transplant recipients receiving everolimus‐facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study - Berger - 2019 - American Journal of Transplantation - Wiley Online Library](https://f1.media.brightcove.com/8/3806881048001/3806881048001_6092895365001_6091008250001-vs.jpg?pubId=3806881048001&videoId=6091008250001)
Two‐year outcomes in de novo renal transplant recipients receiving everolimus‐facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study - Berger - 2019 - American Journal of Transplantation - Wiley Online Library
![Diagnostics | Free Full-Text | Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting | HTML Diagnostics | Free Full-Text | Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting | HTML](https://www.mdpi.com/diagnostics/diagnostics-11-00733/article_deploy/html/images/diagnostics-11-00733-g006.png)
Diagnostics | Free Full-Text | Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting | HTML
![FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer | npj Breast Cancer FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-021-00331-8/MediaObjects/41523_2021_331_Fig3_HTML.png)